LEQEMBI6d ago
FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment
The FDA has granted approval for a subcutaneous starting dose regimen of lecanemab, known as Leqembi. This regulatory decision allows individuals with early-stage Alzheimer disease to initiate treatment at home through w…